Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

Exclusion Criteria

• •Any findings from the medical examination (including medical history, physical examination, vital signs, laboratory tests and ECG) deviating from normal and deemed by the investigator to be of clinical relevance
• •Relevant diseases potentially interfering with the study objectives within the 4 weeks before screening or between screening and randomization
• •Any febrile illness within the four weeks before screening or between screening and randomization
• •Any known presence or history of severe allergies, non-allergic drug reactions, or multiple drug allergies
• •Known or suspected malignant tumors or carcinoma in situ
• •Any history of malignant tumors
• •Any known or suspected benign tumors of the liver and/or pituitary gland
• •Known liver disease: existing acute or chronic progressive liver disease, e.g. disturbance of bilirubin excretion (Dubin-Johnson and Rotor syndromes); disturbances of bile secretion and flow (cholestasis); presence or history of liver tumors (benign or malignant). Note: According to this criterion there must have been an interval of at least 6 months between the subsidence of any viral hepatitis (normalization of liver parameters) and the screening visit.